These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30861342)

  • 1. IID572: A New Potentially Best-In-Class β-Lactamase Inhibitor.
    Reck F; Bermingham A; Blais J; Casarez A; Colvin R; Dean CR; Furegati M; Gamboa L; Growcott E; Li C; Lopez S; Metzger L; Nocito S; Ossola F; Phizackerley K; Rasper D; Shaul J; Shen X; Simmons RL; Tang D; Tashiro K; Yue Q
    ACS Infect Dis; 2019 Jul; 5(7):1045-1051. PubMed ID: 30861342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 2-Sulfinyl-Diazabicyclooctane Derivatives, Potential Oral β-Lactamase Inhibitors for Infections Caused by Serine β-Lactamase-Producing Enterobacterales.
    Fujiu M; Yokoo K; Sato J; Shibuya S; Komano K; Kusano H; Sato S; Aoki T; Kohira N; Kanazawa S; Watari R; Kawachi T; Hirakawa Y; Nagamatsu D; Kashiwagi E; Maki H; Yamawaki K
    J Med Chem; 2021 Jul; 64(13):9496-9512. PubMed ID: 34143627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases.
    Durand-Réville TF; Comita-Prevoir J; Zhang J; Wu X; May-Dracka TL; Romero JAC; Wu F; Chen A; Shapiro AB; Carter NM; McLeod SM; Giacobbe RA; Verheijen JC; Lahiri SD; Sacco MD; Chen Y; O'Donnell JP; Miller AA; Mueller JP; Tommasi RA
    J Med Chem; 2020 Nov; 63(21):12511-12525. PubMed ID: 32658473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.
    Morinaka A; Tsutsumi Y; Yamada M; Suzuki K; Watanabe T; Abe T; Furuuchi T; Inamura S; Sakamaki Y; Mitsuhashi N; Ida T; Livermore DM
    J Antimicrob Chemother; 2015 Oct; 70(10):2779-86. PubMed ID: 26089439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of OP0595/β-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactamases.
    Livermore DM; Mushtaq S; Warner M; Woodford N
    J Antimicrob Chemother; 2015 Nov; 70(11):3032-41. PubMed ID: 26311835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diazabicyclooctane Functionalization for Inhibition of β-Lactamases from Enterobacteria.
    Bouchet F; Atze H; Fonvielle M; Edoo Z; Arthur M; Ethève-Quelquejeu M; Iannazzo L
    J Med Chem; 2020 May; 63(10):5257-5273. PubMed ID: 32242415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition.
    Iqbal Z; Sun J; Yang H; Ji J; He L; Zhai L; Ji J; Zhou P; Tang D; Mu Y; Wang L; Yang Z
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
    Durand-Réville TF; Guler S; Comita-Prevoir J; Chen B; Bifulco N; Huynh H; Lahiri S; Shapiro AB; McLeod SM; Carter NM; Moussa SH; Velez-Vega C; Olivier NB; McLaughlin R; Gao N; Thresher J; Palmer T; Andrews B; Giacobbe RA; Newman JV; Ehmann DE; de Jonge B; O'Donnell J; Mueller JP; Tommasi RA; Miller AA
    Nat Microbiol; 2017 Jun; 2():17104. PubMed ID: 28665414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction of a Thio Functional Group to Diazabicyclooctane: An Effective Modification to Potentiate the Activity of β-Lactams against Gram-Negative Bacteria Producing Class A, C, and D Serine β-Lactamases.
    Fujiu M; Yokoo K; Sato J; Shibuya S; Komano K; Kusano H; Sato S; Aoki T; Kohira N; Miyagawa S; Kawachi T; Yamawaki K
    ACS Infect Dis; 2020 Nov; 6(11):3034-3047. PubMed ID: 33147950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interplay between β-lactamases and new β-lactamase inhibitors.
    Bush K; Bradford PA
    Nat Rev Microbiol; 2019 May; 17(5):295-306. PubMed ID: 30837684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Mutations in the
    Ranjitkar S; Reck F; Ke X; Zhu Q; McEnroe G; Lopez SL; Dean CR
    mSphere; 2019 Jul; 4(4):. PubMed ID: 31270174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Characterization of Diazabicyclooctane β-Lactam "Enhancers" in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa.
    Rajavel M; Kumar V; Nguyen H; Wyatt J; Marshall SH; Papp-Wallace KM; Deshpande P; Bhavsar S; Yeole R; Bhagwat S; Patel M; Bonomo RA; van den Akker F
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234.
    Papp-Wallace KM; Nguyen NQ; Jacobs MR; Bethel CR; Barnes MD; Kumar V; Bajaksouzian S; Rudin SD; Rather PN; Bhavsar S; Ravikumar T; Deshpande PK; Patil V; Yeole R; Bhagwat SS; Patel MV; van den Akker F; Bonomo RA
    J Med Chem; 2018 May; 61(9):4067-4086. PubMed ID: 29627985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthetic approaches towards avibactam and other diazabicyclooctane β-lactamase inhibitors.
    Peilleron L; Cariou K
    Org Biomol Chem; 2020 Feb; 18(5):830-844. PubMed ID: 31956877
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Monogue ML; Giovagnoli S; Bissantz C; Zampaloni C; Nicolau DP
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 30012751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria.
    Livermore DM; Mushtaq S; Warner M; Vickers A; Woodford N
    J Antimicrob Chemother; 2017 May; 72(5):1373-1385. PubMed ID: 28158732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catalytic asymmetric total synthesis of diazabicyclooctane β-lactamase inhibitors avibactam and relebactam.
    Yang Z; Chen Y; Wan L; Cen X; Tang P; Chen F
    Chem Commun (Camb); 2022 Sep; 58(77):10869-10872. PubMed ID: 36074791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.